Clinical trial · Interventional
The Effect of Escitalopram in PCOS
The Effect of Anti Depressive Medicine on Adrenal Activity, Glucose Metabolism, Physical and Mental Health in Polycystic Ovary Syndrome. -A Randomised, Double Blinded, Placebo Controlled Study.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In a randomized study the investigators aim to characterize the effect of antidepressive medicine on quality of life, body composition, adrenal activity and glucose metabolism in PCOS. PCOS is a common endocrine disorder characterized by adrenal and ovarian hyperandrogenaemia, anovulation and insulin resistance. The pathogenesis of PCOS may be described by a vicious cycle involving insulin resistance which stimulates ovarian and adrenal hyper androgenaemia and leads to abdominal obesity, causing increased risk for diabetes and cardiovascular disease. Adrenal hyperactivity is associated with depression. Antidepressive medicine may normalize pituitary-adrenal activity and in animal studies antidepressive medicine improved adrenal hyperactivity and normalized insulin sensitivity.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Escitalopram 20 mg | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Cipralex
- description
- Escitalopram 20 mg x 1 for 12 weeks
- interventionNames
- Drug: Placebo
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Placebo 20 mg x 1 for 12 weeks
- interventionNames
- Drug: Escitalopram 20 mg
Primary outcomes (2)
- measure
- Adrenal activity in urine
- timeFrame
- 12 weeks
- description
- Cortisol in 24 h urine
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * BMI \> 25 and \<5 * Age 18-45 years * Two of the following 1: an/oligomenorhea, 2: Hirsutism or hyper androgenaemia, 3: PCO in trans vaginal ultrasound * Other diagnoses excluded Exclusion Criteria: * Post menopausal * Diabetes * Eating disorder * Psychiatric disorder * Usage of oral anticonceptives or metformin * Pregnancy or planned pregnancy in the treatment period * Non-caucasian * Epilepsy * Allergy to the medicine
References
Publications (0)
Data not yet available